Publications by authors named "Jordan Bittengle"
Background: Deposition of wild-type or mutant transthyretin (TTR) amyloid fibrils in the myocardium causes TTR amyloid cardiomyopathy (ATTR-CM). Targeted therapeutics for ATTR-CM include TTR stabilizers (tafamidis and diflunisal) and oligonucleotide drugs (revusiran, patisiran, and inotersen). TTR stabilizers prevent dissociation of transthyretin tetramers.
View Article and Find Full Text PDFArticle Synopsis
- AL amyloidosis is a serious plasma-cell neoplasm with a poor prognosis, and while it shares some chromosomal abnormalities with Multiple Myeloma, the prognostic significance of these abnormalities using Fluorescent in situ hybridization (FISH) in AL amyloidosis is not well understood.
- The study reviewed 113 AL amyloidosis patients, identifying key FISH cytogenetic abnormalities and their impacts on progression-free survival (PFS) and overall survival (OS) in high-risk cardiac patients.
- Results showed that 76% of patients had abnormal FISH, particularly with translocation t(11;14) and hyperdiploidy, where hyperdiploidy was linked
Background: Autologous stem cell transplantation (ASCT) remains an effective treatment option for many patients with systemic light chain (AL) amyloidosis. While maintenance post ASCT in multiple myeloma is now standard, the decision to utilize maintenance in AL amyloidosis remains largely unexplored. The present study aims to determine the prognostic significance of utilizing maintenance therapy following ASCT and assess the impact of fluorescent in situ hybridization (FISH) abnormalities, bone marrow plasma cell burden (BMPC), and degree of organ involvement on this decision.
View Article and Find Full Text PDF